Research programme: cancer immunotherapies - Asterias Biotherapeutics

Drug Profile

Research programme: cancer immunotherapies - Asterias Biotherapeutics

Alternative Names: Antigen-presenting allogeneic dendritic cells; AST-VAC2; AST-VAC2 allogeneic dendritic cell cancer vaccine - Asterias Biotherapeutics; GRNVAC 2; VAC 2

Latest Information Update: 28 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Geron Corporation
  • Developer Asterias Biotherapeutics; Cancer Research UK
  • Class Cell therapies; Dendritic cell vaccines
  • Mechanism of Action Cell replacements; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Lung cancer
  • Discontinued Transplant rejection

Most Recent Events

  • 26 Sep 2017 Asterias Biotherapeutics receives regulatory approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) and the NHS Research Ethics Committee (REC) for the conduction of a phase I/IIa trial in Non-small cell lung cancer in United Kingdom
  • 03 Aug 2017 Asterias and Cancer Research UK plan to conduct a phase I/IIa trial in Non-small cell lung cancer the second half of 2017
  • 28 Mar 2017 Asterias Biotherapeutics has patent protection for AST VAC2 in South Korea, Israel, Singapore (Asterias Biotherapeutics 10-K; March 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top